European LeukemiaNet 2020 recommendations for treating chronic
myeloid leukemia

J 2020

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

HOCHHAUS, A.; M. BACCARANI; R. T. SILVER; C. SCHIFFER; J. F. APPERLEY et al.

Základní údaje

Originální název

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

Autoři

Vydání

Leukemia, London, Nature Publishing Group, 2020, 0887-6924

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 11.528

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/20:00116551

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

European LeukemiaNet; chronic myeloid leukemia

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 2. 10. 2020 09:17, Mgr. Tereza Miškechová

Anotace

V originále

The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. Another goal is achieving a stable deep molecular response (DMR) and discontinuing medication for treatment-free remission (TFR). The European LeukemiaNet convened an expert panel to critically evaluate and update the evidence to achieve these goals since its previous recommendations. First-line treatment is a tyrosine kinase inhibitor (TKI; imatinib brand or generic, dasatinib, nilotinib, and bosutinib are available first-line). Generic imatinib is the cost-effective initial treatment in CP. Various contraindications and side-effects of all TKIs should be considered. Patient risk status at diagnosis should be assessed with the new EUTOS long-term survival (ELTS)-score. Monitoring of response should be done by quantitative polymerase chain reaction whenever possible. A change of treatment is recommended when intolerance cannot be ameliorated or when molecular milestones are not reached. Greater than 10% BCR-ABL1 at 3 months indicates treatment failure when confirmed. Allogeneic transplantation continues to be a therapeutic option particularly for advanced phase CML. TKI treatment should be withheld during pregnancy. Treatment discontinuation may be considered in patients with durable DMR with the goal of achieving TFR.

Citovat

HOCHHAUS, A.; M. BACCARANI; R. T. SILVER; C. SCHIFFER; J. F. APPERLEY; F. CERVANTES; R. E. CLARK; J. E. CORTES; M. W. DEININGER; F. GUILHOT; H. HJORTH-HANSEN; T. P. HUGHES; J. J. W. M. JANSSEN; H. M. KANTARJIAN; D. W. KIM; R. A. LARSON; J. H. LIPTON; F. X. MAHON; Jiří MAYER; F. NICOLINI; D. NIEDERWIESER; F. PANE; J. P. RADICH; D. REA; J. RICHTER; G. ROSTI; P. ROUSSELOT; G. SAGLIO; S. SAUSSELE; S. SOVERINI; J. L. STEEGMANN; A. TURKINA; A. ZARITSKEY a R. HEHLMANN. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. London: Nature Publishing Group, 2020, roč. 34, č. 4, s. 966-984. ISSN 0887-6924. Dostupné z: https://doi.org/10.1038/s41375-020-0776-2.

@article{1682197,
   author = {Hochhaus, A. and Baccarani, M. and Silver, R. T. and Schiffer, C. and Apperley, J. F. and Cervantes, F. and Clark, R. E. and Cortes, J. E. and Deininger, M. W. and Guilhot, F. and HjorthandHansen, H. and Hughes, T. P. and Janssen, J. J. W. M. and Kantarjian, H. M. and Kim, D. W. and Larson, R. A. and Lipton, J. H. and Mahon, F. X. and Mayer, Jiří and Nicolini, F. and Niederwieser, D. and Pane, F. and Radich, J. P. and Rea, D. and Richter, J. and Rosti, G. and Rousselot, P. and Saglio, G. and Saussele, S. and Soverini, S. and Steegmann, J. L. and Turkina, A. and Zaritskey, A. and Hehlmann, R.},
   article_location = {London},
   article_number = {4},
   doi = {https://doi.org/10.1038/s41375-020-0776-2},
   keywords = {European LeukemiaNet; chronic myeloid leukemia},
   language = {eng},
   issn = {0887-6924},
   journal = {Leukemia},
   title = {European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia},
   url = {https://www.nature.com/articles/s41375-020-0776-2.pdf},
   volume = {34},
   year = {2020}
}

TY  - JOUR
ID  - 1682197
AU  - Hochhaus, A. - Baccarani, M. - Silver, R. T. - Schiffer, C. - Apperley, J. F. - Cervantes, F. - Clark, R. E. - Cortes, J. E. - Deininger, M. W. - Guilhot, F. - Hjorth-Hansen, H. - Hughes, T. P. - Janssen, J. J. W. M. - Kantarjian, H. M. - Kim, D. W. - Larson, R. A. - Lipton, J. H. - Mahon, F. X. - Mayer, Jiří - Nicolini, F. - Niederwieser, D. - Pane, F. - Radich, J. P. - Rea, D. - Richter, J. - Rosti, G. - Rousselot, P. - Saglio, G. - Saussele, S. - Soverini, S. - Steegmann, J. L. - Turkina, A. - Zaritskey, A. - Hehlmann, R.
PY  - 2020
TI  - European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
JF  - Leukemia
VL  - 34
IS  - 4
SP  - 966-984
EP  - 966-984
PB  - Nature Publishing Group
SN  - 08876924
KW  - European LeukemiaNet
KW  - chronic myeloid leukemia
UR  - https://www.nature.com/articles/s41375-020-0776-2.pdf
L2  - https://www.nature.com/articles/s41375-020-0776-2.pdf
N2  - The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. Another goal is achieving a stable deep molecular response (DMR) and discontinuing medication for treatment-free remission (TFR). The European LeukemiaNet convened an expert panel to critically evaluate and update the evidence to achieve these goals since its previous recommendations. First-line treatment is a tyrosine kinase inhibitor (TKI; imatinib brand or generic, dasatinib, nilotinib, and bosutinib are available first-line). Generic imatinib is the cost-effective initial treatment in CP. Various contraindications and side-effects of all TKIs should be considered. Patient risk status at diagnosis should be assessed with the new EUTOS long-term survival (ELTS)-score. Monitoring of response should be done by quantitative polymerase chain reaction whenever possible. A change of treatment is recommended when intolerance cannot be ameliorated or when molecular milestones are not reached. Greater than 10% BCR-ABL1 at 3 months indicates treatment failure when confirmed. Allogeneic transplantation continues to be a therapeutic option particularly for advanced phase CML. TKI treatment should be withheld during pregnancy. Treatment discontinuation may be considered in patients with durable DMR with the goal of achieving TFR.
ER  -

HOCHHAUS, A.; M. BACCARANI; R. T. SILVER; C. SCHIFFER; J. F. APPERLEY; F. CERVANTES; R. E. CLARK; J. E. CORTES; M. W. DEININGER; F. GUILHOT; H. HJORTH-HANSEN; T. P. HUGHES; J. J. W. M. JANSSEN; H. M. KANTARJIAN; D. W. KIM; R. A. LARSON; J. H. LIPTON; F. X. MAHON; Jiří MAYER; F. NICOLINI; D. NIEDERWIESER; F. PANE; J. P. RADICH; D. REA; J. RICHTER; G. ROSTI; P. ROUSSELOT; G. SAGLIO; S. SAUSSELE; S. SOVERINI; J. L. STEEGMANN; A. TURKINA; A. ZARITSKEY a R. HEHLMANN. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. \textit{Leukemia}. London: Nature Publishing Group, 2020, roč.~34, č.~4, s.~966-984. ISSN~0887-6924. Dostupné z: https://doi.org/10.1038/s41375-020-0776-2.

Přehled o publikaci